PT1135513E - Terapia génica mediada por adenovírus - Google Patents

Terapia génica mediada por adenovírus Download PDF

Info

Publication number
PT1135513E
PT1135513E PT99971860T PT99971860T PT1135513E PT 1135513 E PT1135513 E PT 1135513E PT 99971860 T PT99971860 T PT 99971860T PT 99971860 T PT99971860 T PT 99971860T PT 1135513 E PT1135513 E PT 1135513E
Authority
PT
Portugal
Prior art keywords
adenovirus
tumor
patients
gene
resection
Prior art date
Application number
PT99971860T
Other languages
English (en)
Portuguese (pt)
Inventor
Seppo Yla-Herttuala
Anu-Maaria Sandmair
Sami Loimas
Matti Vapalahti
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1135513(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of PT1135513E publication Critical patent/PT1135513E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT99971860T 1998-11-06 1999-11-05 Terapia génica mediada por adenovírus PT1135513E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy

Publications (1)

Publication Number Publication Date
PT1135513E true PT1135513E (pt) 2006-12-29

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99971860T PT1135513E (pt) 1998-11-06 1999-11-05 Terapia génica mediada por adenovírus

Country Status (18)

Country Link
US (1) US6579855B1 (cg-RX-API-DMAC7.html)
EP (1) EP1135513B2 (cg-RX-API-DMAC7.html)
JP (1) JP4733833B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020013473A (cg-RX-API-DMAC7.html)
CN (1) CN1184321C (cg-RX-API-DMAC7.html)
AT (1) ATE341639T1 (cg-RX-API-DMAC7.html)
AU (1) AU749451B2 (cg-RX-API-DMAC7.html)
CA (1) CA2348624C (cg-RX-API-DMAC7.html)
CY (1) CY1106198T1 (cg-RX-API-DMAC7.html)
DE (1) DE69933468T3 (cg-RX-API-DMAC7.html)
DK (1) DK1135513T4 (cg-RX-API-DMAC7.html)
ES (1) ES2273521T5 (cg-RX-API-DMAC7.html)
GB (1) GB9824437D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0104046A3 (cg-RX-API-DMAC7.html)
NO (1) NO330776B1 (cg-RX-API-DMAC7.html)
PL (1) PL193076B1 (cg-RX-API-DMAC7.html)
PT (1) PT1135513E (cg-RX-API-DMAC7.html)
WO (1) WO2000028059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) * 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
AU2024207005A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
KR20260113057A (ko) 2023-11-14 2026-07-21 리제너론 파아마슈티컬스, 인크. 조작된 중쇄 가변 도메인 및 이의 용도
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
US6579855B1 (en) 2003-06-17
AU749451B2 (en) 2002-06-27
DE69933468D1 (de) 2006-11-16
HUP0104046A3 (en) 2003-09-29
ES2273521T5 (es) 2011-12-28
CY1106198T1 (el) 2011-06-08
CN1325450A (zh) 2001-12-05
DE69933468T2 (de) 2007-01-11
CA2348624A1 (en) 2000-05-18
NO20012220L (no) 2001-05-04
NO20012220D0 (no) 2001-05-04
AU1385100A (en) 2000-05-29
EP1135513B1 (en) 2006-10-04
ATE341639T1 (de) 2006-10-15
JP4733833B2 (ja) 2011-07-27
PL349489A1 (en) 2002-07-29
PL193076B1 (pl) 2007-01-31
NO330776B1 (no) 2011-07-11
HUP0104046A2 (hu) 2002-01-28
EP1135513B2 (en) 2011-08-10
DE69933468T3 (de) 2012-01-19
KR20020013473A (ko) 2002-02-20
CN1184321C (zh) 2005-01-12
DK1135513T4 (da) 2011-11-21
DK1135513T3 (da) 2006-11-27
WO2000028059A1 (en) 2000-05-18
GB9824437D0 (en) 1999-01-06
ES2273521T3 (es) 2007-05-01
CA2348624C (en) 2012-07-31
JP2002529097A (ja) 2002-09-10
EP1135513A1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
ES2273521T5 (es) Terapia génica mediante adenovirus.
JP4213201B2 (ja) 固型腫瘍、乳頭腫および疣贅の遺伝子治療
ES2257051T3 (es) Administracion potenciada por conveccion de vectores aav que codifican aadc.
US7182944B2 (en) Methods of increasing distribution of nucleic acids
ES2698571T3 (es) Sistema de expresión para una terapia genética selectiva
JP3778930B2 (ja) 動脈平滑筋細胞増殖の抑制
US7186698B2 (en) Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
AU749467B2 (en) Compositions and methods for inducing gene expression
SK285969B6 (sk) Prípravky na liečenie cicavčích nádorových alebo hyperproliferatívnych buniek
US6596269B1 (en) Methods of treating chronic pain
US20010012835A1 (en) Method of enhancing the effectiveness of dck phosphorylated molecules
Huang et al. Exogenous wt-p53 enhances the antitumor effect of HSV-TK/GCV on C6 glioma cells
US20170283829A1 (en) Sprr1a as a genetic target for treating neurodegenerative diseases
US6248351B1 (en) Human PEA3 is a tumor suppressor for cancer cells
Shimizu et al. Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma
JP2003501362A (ja) 脈管形成インヒビターとしてのc−cam
US20040180845A1 (en) Methods and compositions for modulating glycogen synthesis and breakdown
MXPA01004410A (es) Terapia de gen mediada por adenovirus
WO1998019686A9 (en) Therapeutic methods for vascular injury
KR100389526B1 (ko) 재조합아데노바이러스벡터및사용방법
CA2425820C (en) Convection-enhanced delivery of aav vectors
Duzgunes Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma
Brown et al. Retroviruses and DNA: gene therapy for brain tumours
WO2001032686A2 (en) Arginine kinase